INTERLEUKIN-10 INHIBITS THE ELICITATION PHASE OF ALLERGIC CONTACT HYPERSENSITIVITY

被引:52
作者
KONDO, S [1 ]
MCKENZIE, RC [1 ]
SAUDER, DN [1 ]
机构
[1] UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV DERMATOL,TORONTO,ON M4N 3M5,CANADA
关键词
IFN-GAMMA; ELICITATION PHASE; DTH;
D O I
10.1111/1523-1747.ep12413470
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Interleukin-10 (IL-10) is known to play a major role in suppressing immune and inflammatory responses by inhibiting the production of proinflammatory cytokines. Therefore, we hypothesized that IL-10 might be capable of suppressing allergic contact hypersensitivity. BALB/c mice were sensitized on the dorsal skin with dinitrofluorobenzene and challenged on the ears 6 d later. The effect of IL-10 on the elicitation phase of contact sensitization was determined by its intradermal injection into the pinnae of the mice at doses of 0.1-100 ng. At 24 and 48 h after challenge, ear swelling was suppressed in a dose-dependent manner by injection of IL-10 at doses of 10-100 ng. Maximal inhibition of ear swelling (46.9%) was observed after injection of 100 ng of IL-10. IL-10-injected ear skins showed less inflammatory cell infiltration and decreased edema at the dermis compared with controls. Because IL-10 is known to inhibit Th1 cytokines such as interferon-gamma, we examined whether the suppressive effect of IL-10 on ear swelling was accompanied by IL-10-induced inhibition of interferon-gamma. We found that IL-10 application suppressed interferon-gamma mRNA upregulation in challenged skin. Our results suggest that IL-10 significantly modifies the elicitation of allergic contact sensitivity reactions.
引用
收藏
页码:811 / 814
页数:4
相关论文
共 38 条
[1]   IMMUNE REGULATION IN ALLERGIC AND IRRITANT SKIN REACTIONS [J].
BAADSGAARD, O ;
WANG, T .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1991, 30 (03) :161-172
[2]   RECOMBINANT GAMMA-INTERFERON INDUCES HLA-DR EXPRESSION ON CULTURED HUMAN KERATINOCYTES [J].
BASHAM, TY ;
NICKOLOFF, BJ ;
MERIGAN, TC ;
MORHENN, VB .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1984, 83 (02) :88-90
[3]  
BELSITO DV, 1989, J IMMUNOL, V143, P1530
[4]  
CHER DJ, 1987, J IMMUNOL, V138, P3688
[5]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[6]  
CUMBERBATCH M, 1992, IMMUNOLOGY, V75, P257
[7]  
ENK AH, 1992, J IMMUNOL, V149, P92
[8]  
ENK AH, 1993, J IMMUNOL, V151, P2390
[9]  
ENK AH, 1992, P NATL ACAD SCI USA, V89, P1358
[10]  
ENK AH, 1994, J EXP MED, V179, P1392